BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human ...
The company states: “Virpax Pharmaceutical would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology and showing no moderate to severe adverse events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback